183 related articles for article (PubMed ID: 32427225)
1. Antiviral Peptides: Identification and Validation.
Agarwal G; Gabrani R
Int J Pept Res Ther; 2021; 27(1):149-168. PubMed ID: 32427225
[TBL] [Abstract][Full Text] [Related]
2. Phage display of combinatorial peptide libraries: application to antiviral research.
Castel G; Chtéoui M; Heyd B; Tordo N
Molecules; 2011 Apr; 16(5):3499-518. PubMed ID: 21522083
[TBL] [Abstract][Full Text] [Related]
3. Recent Patents and FDA-Approved Drugs Based on Antiviral Peptides and Other Peptide-Related Antivirals.
Mousavi Maleki MS; Sardari S; Ghandehari Alavijeh A; Madanchi H
Int J Pept Res Ther; 2023; 29(1):5. PubMed ID: 36466430
[TBL] [Abstract][Full Text] [Related]
4. Broad-Spectrum Antiviral Entry Inhibition by Interfacially Active Peptides.
Hoffmann AR; Guha S; Wu E; Ghimire J; Wang Y; He J; Garry RF; Wimley WC
J Virol; 2020 Nov; 94(23):. PubMed ID: 32907984
[TBL] [Abstract][Full Text] [Related]
5. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
6. Virtual Screening of Peptide Libraries: The Search for Peptide-Based Therapeutics Using Computational Tools.
Vincenzi M; Mercurio FA; Leone M
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339078
[TBL] [Abstract][Full Text] [Related]
7. A Review: The Antiviral Activity of Cyclic Peptides.
Chia LY; Kumar PV; Maki MAA; Ravichandran G; Thilagar S
Int J Pept Res Ther; 2023; 29(1):7. PubMed ID: 36471676
[TBL] [Abstract][Full Text] [Related]
8. Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review.
Akram M; Tahir IM; Shah SMA; Mahmood Z; Altaf A; Ahmad K; Munir N; Daniyal M; Nasir S; Mehboob H
Phytother Res; 2018 May; 32(5):811-822. PubMed ID: 29356205
[TBL] [Abstract][Full Text] [Related]
9. Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.
Pizzorno A; Terrier O; Nicolas de Lamballerie C; Julien T; Padey B; Traversier A; Roche M; Hamelin ME; Rhéaume C; Croze S; Escuret V; Poissy J; Lina B; Legras-Lachuer C; Textoris J; Boivin G; Rosa-Calatrava M
Front Immunol; 2019; 10():60. PubMed ID: 30761132
[TBL] [Abstract][Full Text] [Related]
10. Cationic host defence peptides: potential as antiviral therapeutics.
Gwyer Findlay E; Currie SM; Davidson DJ
BioDrugs; 2013 Oct; 27(5):479-93. PubMed ID: 23649937
[TBL] [Abstract][Full Text] [Related]
11. Current antiviral drugs and their analysis in biological materials - Part II: Antivirals against hepatitis and HIV viruses.
Nováková L; Pavlík J; Chrenková L; Martinec O; Červený L
J Pharm Biomed Anal; 2018 Jan; 147():378-399. PubMed ID: 29031512
[TBL] [Abstract][Full Text] [Related]
12. Antiviral drugs for viruses other than human immunodeficiency virus.
Razonable RR
Mayo Clin Proc; 2011 Oct; 86(10):1009-26. PubMed ID: 21964179
[TBL] [Abstract][Full Text] [Related]
13. Antiviral Peptides with in vivo Activity: Development and Modes of Action.
Gao B; Zhao D; Li L; Cheng Z; Guo Y
Chempluschem; 2021 Nov; 86(12):1547-1558. PubMed ID: 34755499
[TBL] [Abstract][Full Text] [Related]
14. Linear and dendrimeric antiviral peptides: design, chemical synthesis and activity against human respiratory syncytial virus.
Kozhikhova KV; Shilovskiy IP; Shatilov AA; Timofeeva AV; Turetskiy EA; Vishniakova LI; Nikolskii AA; Barvinskaya ED; Karthikeyan S; Smirnov VV; Kudlay DA; Andreev SM; Khaitov MR
J Mater Chem B; 2020 Apr; 8(13):2607-2617. PubMed ID: 32124885
[TBL] [Abstract][Full Text] [Related]
15. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
16. Design and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach.
Hornig J; McGregor A
Expert Opin Drug Discov; 2014 Aug; 9(8):891-915. PubMed ID: 25003658
[TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
18. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
19. The synergistic use of computation, chemistry and biology to discover novel peptide-based drugs: the time is right.
Audie J; Boyd C
Curr Pharm Des; 2010; 16(5):567-82. PubMed ID: 19929848
[TBL] [Abstract][Full Text] [Related]
20. Antiviral Peptide-Based Conjugates: State of the Art and Future Perspectives.
Todorovski T; Kalafatovic D; Andreu D
Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
